Luni Camilla, Shoemaker Jason E, Sanft Kevin R, Petzold Linda R, Doyle Francis J
Department of Chemical Engineering, University of California, Santa Barbara, CA 93106-5080, USA.
BMC Syst Biol. 2010 Nov 24;4:161. doi: 10.1186/1752-0509-4-161.
Robustness is a recognized feature of biological systems that evolved as a defence to environmental variability. Complex diseases such as diabetes, cancer, bacterial and viral infections, exploit the same mechanisms that allow for robust behaviour in healthy conditions to ensure their own continuance. Single drug therapies, while generally potent regulators of their specific protein/gene targets, often fail to counter the robustness of the disease in question. Multi-drug therapies offer a powerful means to restore disrupted biological networks, by targeting the subsystem of interest while preventing the diseased network from reconciling through available, redundant mechanisms. Modelling techniques are needed to manage the high number of combinatorial possibilities arising in multi-drug therapeutic design, and identify synergistic targets that are robust to system uncertainty.
We present the application of a method from robust control theory, Structured Singular Value or μ- analysis, to identify highly effective multi-drug therapies by using robustness in the face of uncertainty as a new means of target discrimination. We illustrate the method by means of a case study of a negative feedback network motif subject to parametric uncertainty.
The paper contributes to the development of effective methods for drug screening in the context of network modelling affected by parametric uncertainty. The results have wide applicability for the analysis of different sources of uncertainty like noise experienced in the data, neglected dynamics, or intrinsic biological variability.
稳健性是生物系统的一个公认特征,它是作为对环境变异性的一种防御机制而进化出来的。诸如糖尿病、癌症、细菌和病毒感染等复杂疾病,利用了在健康状态下允许稳健行为的相同机制来确保自身的持续存在。单一药物疗法虽然通常是其特定蛋白质/基因靶点的有效调节剂,但往往无法对抗所讨论疾病的稳健性。多药物疗法提供了一种强大的手段,通过针对感兴趣的子系统,同时防止患病网络通过可用的冗余机制进行自我修复,从而恢复被破坏的生物网络。需要建模技术来管理多药物治疗设计中出现的大量组合可能性,并识别对系统不确定性具有鲁棒性的协同靶点。
我们展示了一种来自鲁棒控制理论的方法——结构化奇异值或μ分析的应用,通过将面对不确定性时的稳健性作为一种新的靶点判别手段,来识别高效的多药物疗法。我们通过一个受参数不确定性影响的负反馈网络基序的案例研究来说明该方法。
本文有助于在受参数不确定性影响的网络建模背景下开发有效的药物筛选方法。这些结果对于分析不同来源的不确定性,如数据中经历的噪声、被忽略的动力学或内在生物变异性,具有广泛的适用性。